Friday, August 18, 2017

ViraCyte Gets $8.99M Grant

Houston-based biopharmaceuticals developer ViraCyte reported on Thursday that it has received a $8.99M grant, from the Cancer Prevention and Research Institute of Texas (CPRIT). According to the company, the grant will go to support clinical development of its lead product, which is a multivirus-specific T cell immunotherapy. CPRIT provides funding to Texas-based companies developing disruptive, commercially-oriented technologies with the overall goal of improving outcomes in patients with cancer, according to the company.